SCHEMBL1369604

SCHEMBL1369604

COc1ccc(-c2ccccc2C(C)N(c2cccnc2)c2cccnc2)c(OC)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 1/20 0.38
BRD7 Q9NPI1 1/20 0.38
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.34
HSD17B10 Q99714 2/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
PDE10A Q9Y233 3/20 0.34
NPC1 O15118 1/20 0.33
ATM Q13315 1/20 0.33
BCL2L11 O43521 2/20 0.33
BCL2L1 Q07817 2/20 0.33
BID P55957 1/20 0.33
BAK1 Q16611 1/20 0.33
BBC3 Q9BXH1 1/20 0.33
KCNA5 P22460 2/20 0.33
CYP1A2 P05177 1/20 0.32
METAP2 P50579 1/20 0.32
USP1 O94782 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14451459 0.82 POLB (0.42) ALDH1A1HSD17B10NPC1KCNA5CYP1A2
SCHEMBL1369559 0.81 RPS6KA3 (0.42) USP1WDR48
SCHEMBL10094340 0.76 BRD9 (0.49) BRD9BRD7ALDH1A1HPGDRAB9A
SCHEMBL14451464 0.76 KCNA5 (0.38) ALDH1A1HSD17B10GAAKCNA5CYP1A2
SCHEMBL14450923 0.75 KCNA5 (0.44) RAB9AGAANPC1KCNA5
SCHEMBL14450920 0.75 KCNA5 (0.40) ALDH1A1HPGDRAB9AGAANPC1
SCHEMBL14450922 0.75 KCNA5 (0.36) ALDH1A1GAAKCNA5USP1WDR48
SCHEMBL1369553 0.75 KCNA5 (0.43) ALDH1A1GAAKCNA5CYP1A2USP1
SCHEMBL4977322 0.74 ALDH1A1 (0.38) BRD9BRD7ALDH1A1HPGDRAB9A
SCHEMBL1367002 0.74 KCNA5 (0.45) GAAPDE10AKCNA5USP1WDR48

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067607-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2011-11-29 US claimed
US-20100004229-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2010-01-07 US claimed
US-8067607-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2011-11-29 US disclosed
US-20100004229-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2010-01-07 US disclosed
EP-1993551-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-11-26 EP disclosed
WO-2007089735-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed
WO-2007089735-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004229-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 BRD9 1204/4885BRD7 667/4885ALDH1A1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.